印度将进一步降低了对心脏药物洗脱支架的报销额度
2013年4月,我公司报道,印度中央政府保健计划(CGHS)减少了心脏医疗器械产品的报销额度-如心脏的药物洗脱支架(DES)的报销额度减少了60%。以前,美国FDA批准的心脏药物洗脱支架可以报销1,200美元。而如今只报销$460。欧盟和印度批准支架报销额度也下调到$460。 Read More
2013年4月,我公司报道,印度中央政府保健计划(CGHS)减少了心脏医疗器械产品的报销额度-如心脏的药物洗脱支架(DES)的报销额度减少了60%。以前,美国FDA批准的心脏药物洗脱支架可以报销1,200美元。而如今只报销$460。欧盟和印度批准支架报销额度也下调到$460。 Read More
2013年尽管全球私人基金对医疗行业的投资下降了一半以上,但对亚洲的投资在持续增长。2011年和2013年间,亚太地区的医疗保健的投资量同比增长了130 %,其中在印度和中国的投资最多。 Read More
The Indian government has allowed pharmaceutical companies to raise the maximum retail prices (MRPs) for drugs. Pursuant to the Drug Price Control Order (DPCO) 2013, essential medicine prices are capped at the average increase of all drugs in a certain segment that... Read More
In April 2013, PBM noted in a newsbrief that India's Central Government Health Scheme (CGHS) had reduced its reimbursement prices for cardio products -- such as drug-eluting stents (DES) -- by up to 60%. Stents that had been approved by the U.S.... Read More
Although the value of global private equity deals in the healthcare sector fell by more than half over 2013, investment in Asia is booming. Between 2011 and 2013, the volume of investment in Asia-Pacific healthcare grew 130%, with India and China leading... Read More
为了减少今后专利诉讼风险,印度专利局(IPO)于2014年3月7日公布了新药专利申请指导原则草案。并给出两星期时间,公开征求公众意见。该指导原则草案的修订, 源于印度政府拒绝诺华(Novartis)格列卫(Glivec)7年专利申请的诉讼案。 新的药品专利指导原则草案明确指出“增强治疗效果”是决定是否授予改进药物新专利的唯一标准。“增强治疗效果”替代了以前“增强效果”的提法。这种措辞的变化源于法院对诺华(Novartis)案的裁决。 虽然指导原则草案并非法律,但指导原则草案是专利申请的规范。专利法的相关规定(专利法第3(d)条)并不与新发布的药品专利指导原则草案冲突。而且,最高法院认定新草案中“增强治疗效果”的提法可以在实践中加强监管的力度和水平。 这意味着,在印度得到创新药物产品的专利将会变得越来越困难。药品专利指导原则草案如果得到通过,也将加强印度对药医产品专利申请的程序规范性和管理部门行政执法的一致性。 Read More
In order to reduce the risk of future patent litigations, the Indian Patent Office (IPO) announced draft guidelines for drug patents on March 7, 2014. A two week period was given for public comment. This draft guideline revision comes in the wake... Read More
Sourcing medical devices in Asia has become a common practice as more companies are taking advantage of the lower overhead, lower labor costs and increasing technical capabilities available in the Asian countries. Medical device companies can buy and manufacture a wide array... Read More
This report on Asian CROs provides a comprehensive list of contract research organizations in Asia. The countries covered include: Japan, Taiwan, Korea, Singapore, Hong Kong, India, China, Malaysia, Philippines, Indonesia, Thailand and Vietnam. Included for each CRO are contact information, description of... Read More
Drug companies have often conducted clinical trials in India because of the country’s low costs, patient availability and technically proficient personnel. But in late 2012, amended regulations made securing permission for a clinical trial a much more rigorous process. This has lowered... Read More